Prot#CCFZ533A2202: A 12-month, Open-label, Multicenter, Randomized, Safety, Efficacy, Pharmacokinetic (PK) and Pharmacodynamic (PD) Study of Two Regimens of Anti-CD40 Monoclonal Antibody,CFZ533 vs. Standard of Care Control, in Adult De Novo Liver Transpla

  • Levitsky, Josh (PD/PI)

Project: Research project

Project Details

StatusFinished
Effective start/end date4/1/19 → 8/31/23

Funding

  • Novartis Pharmaceuticals Corporation (CCFZ533A2202)